Hepatocellular Carcinoma News and Research RSS Feed - Hepatocellular Carcinoma News and Research

HBcrAg may predict HCC development

HBcrAg may predict HCC development

Research suggests a role for hepatitis B core-related antigen in the prediction of hepatocellular carcinoma development in nucleos(t)ide analogue treatment-naïve patients with chronic hepatitis B virus infection. [More]
WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

Japanese researchers have found that serum levels of glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein are a useful marker of not only the degree of liver fibrosis, but also progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. [More]
HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a 'high rate' of re-developing their illness. [More]
DAA medication could lead to revolution in hepatitis C treatment

DAA medication could lead to revolution in hepatitis C treatment

The cost of treating hepatitis C virus (HCV) could be cut up to 50 percent if mathematical models are used to predict when patients can safely stop taking direct-acting antiviral (DAA) medication, according to a new study by researchers at Loyola University Health System and Loyola University Chicago [More]
Dietary broccoli may protect against liver cancer

Dietary broccoli may protect against liver cancer

Consumption of broccoli has increased in the United States over the last few decades as scientists have reported that eating the vegetable three to five times per week can lower the risk of many types of cancer including breast, prostate, and colon cancers. [More]
Structural movie reveals step-by-step creation of chemical that plays important role in some cancers

Structural movie reveals step-by-step creation of chemical that plays important role in some cancers

An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers. [More]
Experimental nanoparticle therapy shows promise for fighting primary liver cancer

Experimental nanoparticle therapy shows promise for fighting primary liver cancer

An experimental nanoparticle therapy that combines low-density lipoproteins (LDL) and fish oil preferentially kills primary liver cancer cells without harming healthy cells, UT Southwestern Medical Center researchers report. [More]
Cistus extracts attack HIV and Ebola viruses

Cistus extracts attack HIV and Ebola viruses

Scientists at the Helmholtz Zentrum München discover that extracts of the medicinal plant Cistus incanus (Ci) prevent human immunodeficiency viruses from infecting cells. Active antiviral ingredients in the extracts inhibit docking of viral proteins to cells. Antiviral activity of Cistus extracts also targets Ebola- and Marburg viruses. [More]
Genetic profiling ‘feasible’ for paediatric cancer patients

Genetic profiling ‘feasible’ for paediatric cancer patients

Research published in JAMA Oncology demonstrates that tumour and germline molecular profiling is feasible in paediatric cancer patients and can have actionable findings. [More]
STAT4 variant predicts HBV IFNα response

STAT4 variant predicts HBV IFNα response

Variation in the STAT4 gene is associated with response to interferon (IFN)α therapy in patients with hepatitis B e antigen-positive chronic hepatitis B virus infection, suggests research published in Hepatology. [More]
Leading researchers reject proposed link between adeno-associated virus 2 and hepatocellular carcinoma

Leading researchers reject proposed link between adeno-associated virus 2 and hepatocellular carcinoma

The conclusion drawn from a recent study that insertion of adeno-associated virus 2 (AAV2) into human DNA causes mutations leading to the development of hepatocellular carcinoma (HCC) was resoundingly rejected by leading researchers in the fields of gene therapy and molecular genetics. [More]
SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced the initiation of a multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC). [More]
Researchers discover 'triple attack' technique to target liver cancer tumors

Researchers discover 'triple attack' technique to target liver cancer tumors

In an interdisciplinary collaboration between prominent academic and industry investigators, researchers have discovered a novel method for repositioning an FDA-approved anti-cancer compound so it can specifically target liver cancer tumors. A 'triple attack' technique combining chemotherapy, thermal ablation, and hyperthermia provided a highly targeted, yet minimally invasive approach. [More]
HBsAg may persist in chronic HBV patients beyond seroclearance

HBsAg may persist in chronic HBV patients beyond seroclearance

The use of a highly sensitive assay for the detection of hepatitis B surface antigen suggests that HBsAg negativity as evaluated by the conventional test may not be indicative of seroclearance in patients with chronic hepatitis B virus infection. [More]
Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the nine months ended September 30, 2015 and updates on its drug development programs. [More]
Liver's cannabinoid receptors could be targeted to combat liver cancer in some patients

Liver's cannabinoid receptors could be targeted to combat liver cancer in some patients

A new study reveals that the liver's cannabinoid receptors could be targeted to fight liver cancer in some patients; and it offers a way to predict what treatments have the best chance of working. [More]
Researchers find greater genetic diversity among cancer cells than anticipated

Researchers find greater genetic diversity among cancer cells than anticipated

The most rigorous genetic sequencing ever carried out on a single tumor reveals far greater genetic diversity among cancer cells than anticipated. Researchers from the University of Chicago and the Beijing Institute of Genomics estimate that the tumor, about 3.5 centimeters in diameter, contained more than 100 million distinct mutations within the coding regions of its genes—thousands of times more than expected. [More]
Johnson & Johnson signs definitive agreement to purchase Novira Therapeutics

Johnson & Johnson signs definitive agreement to purchase Novira Therapeutics

Johnson & Johnson today announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection. [More]
Cancer DNA in patient's bloodstream could help deliver personalized treatment for liver cancer

Cancer DNA in patient's bloodstream could help deliver personalized treatment for liver cancer

Fragments of cancer DNA circulating in a patient's bloodstream could help doctors deliver more personalized treatment for liver cancer, Japanese researchers report. [More]
Researchers develop multiplexed screening approach to study cancer development in mice

Researchers develop multiplexed screening approach to study cancer development in mice

In a novel use of the CRISPR/Cas9 system, which can be deployed to switch genes off, researchers from Germany, the UK and Spain have developed a multiplexed screening approach to study and model cancer development in mice. The scientists mutated genes in the adult mouse liver uncovering their cancer-causing roles and determining which combinations of genes cooperate to cause liver cancer. [More]
Advertisement